The RhoA inhibitor blocked the PEDF-induced effects in podocytes, which suggests that inhibition or antagonism of serum PEDF may provide a new potential therapeutic strategy for proteinuria in DKD patients. This evidence concerns the gene SERPINF1 and diabetic kidney disease.